Breast Cancer Clinical Trial
Official title:
Psychosocial Outcomes in Online Cancer Support Groups
Purpose: The purpose of this project is to evaluate whether psychosocial outcomes in women
with breast cancer differ based on the format of online group support. This objective will
be addressed by the following specific aims:
1. Specific Aim #1 is to determine if there is a difference in depressive symptoms between
women with breast cancer assigned to one of two treatment conditions: moderated online
support or peer-led online support.
• H1: Women with breast cancer who participate in moderated online support will report
fewer depressive symptoms than women with breast cancer in peer led online support.
2. Specific Aim #2 is to determine if there is a difference in perceived social support
between women with breast cancer who are assigned to one of two treatment conditions:
moderated online support or peer-led online support.
• H2: Women with breast cancer who participate in moderated online support will report
greater perceived social support than women with breast cancer in peer-led online
support.
3. Specific Aim #3 is to determine if there is a difference in quality of life in women
with breast cancer who are assigned to one of two treatment conditions: moderated
online support or peer-led online support.
- H3: Women with breast cancer who participate in moderated online support will
report better quality of life than women with breast cancer in peer-led online
support.
NOTE: Once the study began, it was obvious that we could not prevent anyone from joining a
support group, if that was her choice. We also could not control if participants joined a
second online support group or face-to-face group during the study. Therefore, we decided to
omit a "usual care" (no support) group. The study was completed with just two groups:
moderated and peer-support.
Status | Completed |
Enrollment | 51 |
Est. completion date | July 2009 |
Est. primary completion date | July 2009 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 21 Years and older |
Eligibility |
Inclusion Criteria: Clinical diagnosis of breast cancer - Female - At least 21 years of age - Internet access; Able to read and write English - Have completed treatment for breast cancer in the past 36 months or are receiving treatment - Do not currently belong to an online or face-to-face cancer support group - Internet access Exclusion Criteria: - Male - not diagnosed with breast cancer - under 21 years of age - received treatment more than 36 months ago for breast cancer - no Internet access - unable to read and write English |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
United States | University of Delaware | Newark | Delaware |
Lead Sponsor | Collaborator |
---|---|
Christiana Care Health Services |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Scores on the Personal Resource Questionnaire 85. | The Personal Resource Questionnaire 85 (PRQ85), Part II measures perceived social support and consists of 25 items in a seven-point Likert format which are rated from seven (7) strongly agree, to one (1) strongly disagree. Scores range from 25 to 175 with higher scores indicative of higher levels of perceived social support. Alpha reliability of the PRQ 85 has been demonstrated at >.90 | 16 weeks | No |
Primary | Scores on the CES-D Scale | The Center for Epidemiologic Studies Depression Scale (CES-D) is a 20-item self-report scale widely used in the assessment of depression. Each item is given a rating of 0 to 3, with a potential range of 0 to 60 for the entire scale. Higher scores are associated with depression. The cutoff for the diagnosis of Major Depressive Disorder on the CES-D is 16. The instrument is a reliable measure (Alpha >.85) of depression | 16 weeks | No |
Primary | Scores on the Quality of Life (QOL) Question on the Rotterdam Symptom Check List (RSCL). | The Rotterdam Symptom Checklist (RSCL) measures quality of life in cancer patients. The RSCL checklist includes a QOL life question on a scale of 1 (excellent) to 7 (extremely poor). This was used as a measure of overall QOL. | 16 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |